NCT02813135 2026-01-16
ESMART
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2 Recruiting
Clinical Trials
7 trialsNCT00463814 2025-11-13
AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid Malignancies
AstraZeneca
Phase 1 Active not recruiting
NCT00600496 2025-11-13
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
AstraZeneca
Phase 1 Active not recruiting
NCT01586624 2021-10-07
A Phase I Trial of Vandetanib (AZD6474) and Selumetinib (AZD6244) for Solid Tumours Including Non Small Cell Lung Cancer (VanSel-1)
Cancer Research UK
Phase 1 Completed
NCT01605916 2016-10-21
Investigate the Safety and Tolerability of AZD6244 Monotherapy or + Docetaxel in Japanese Patients With Advanced Solid Malignancies or Non-Small Cell Lung Cancer
AstraZeneca
Phase 1 Completed
NCT02322749 2016-08-31
A Study to Assess the Relative Bioavailability of Process Variants of Selumetinib in Healthy Male Volunteers
AstraZeneca
Phase 1 Completed
NCT02238782 2016-04-05
A Study to Assess the Absolute Bioavailability of Oral Selumetinib in Healthy Male Volunteers.
AstraZeneca
Phase 1 Completed